Osteosarcoma Research Portal logoOsteosarcoma Research Portal

Doxorubicin

. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.

← All drugs · Search the portal

Facts

Topic Fact Source (access date)
First US approval record Drugs@FDA NDA 050467 (Adriamycin, now Pfizer): original approval 7 Aug 1974, about 52 years Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA050467 (accessed 4 Nov 2026)
Mechanism Blocks topoisomerase II, an enzyme cells need to untangle DNA when dividing; also inserts into DNA CRUK doxorubicin page (accessed 31 Oct 2026)
Use in osteosarcoma Part of MAP first line at all ages; with cisplatin alone (AP) for people over 40 or who cannot have high-dose methotrexate. UK SmPC (PL 22472/0003) lists neoadjuvant and adjuvant therapy of osteosarcoma; US label lists metastatic bone sarcomas entries.json (portal export), sources opened 31 Oct to 3 Nov 2026; UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026)
Combined with Methotrexate and cisplatin (MAP); cisplatin (AP); with ifosfamide and cisplatin (API-AI) for adults in France UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026); treatment_by_country.md
Results EURAMOS-1 MAP cohort: 5-year event-free survival 54%, overall survival 71%. No single-drug response figure in osteosarcoma opened this run EURAMOS-1 full cohort, Smeland et al., Eur J Cancer 2019, doi:10.1016/j.ejca.2018.11.027 (PMID 30685685), abstract accessed 4 Nov 2026
Side effects Heart muscle damage, linked to total lifetime dose; low blood counts; hair loss; sickness; mouth sores. CCSS: about 7.8% of MAP survivors had heart failure by 20 years CRUK (31 Oct 2026); https://pmc.ncbi.nlm.nih.gov/articles/PMC11343645/ (3 Nov 2026)
Owner and generic status Produced by the bacterium Streptomyces peucetius var. caesius; first described by Arcamone and colleagues in 1969; now generic; US NDA holder Pfizer Arcamone et al., Biotechnol Bioeng 1969, doi:10.1002/bit.260110607 (accessed 4 Nov 2026); eMC SmPC https://www.medicines.org.uk/emc/product/8443/smpc (accessed 4 Nov 2026) (names Streptomyces); Drugs@FDA NDA050467 (accessed 4 Nov 2026)
Regulatory UK: e.g. Seacross PL 41013/0003 (sarcoma, paediatric tumours). EU (Ireland, national licence): Accord PA2315/083/001 lists neoadjuvant and adjuvant therapy of osteosarcoma. US: bone sarcomas. China: domestic approval e.g. Zhejiang Hisun, H20041318. In CSCO MAP eMC SmPC https://www.medicines.org.uk/emc/product/8443/smpc (accessed 4 Nov 2026); HPRA SmPC https://assets.hpra.ie/products/Human/27561/Licence_PA2315-083-001_20022024123027.pdf (accessed 4 Nov 2026); NMPA approval number H20041318 via yaopinnet.com mirror, https://www.yaopinnet.com/h/h18/H20041318.htm (accessed 4 Nov 2026); official NMPA register (datasearch.nmpa.gov.cn) returned HTTP 412 to automated access
Also worth noting Dexrazoxane reduces doxorubicin heart damage; US label limited to women with metastatic breast cancer after 300 mg/m2 doxorubicin openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dexrazoxane%22 (accessed 4 Nov 2026)

Hypotheses and open points (not established fact)